Novo Nordisk shares plummeted as much as 14% after the Danish pharmaceutical giant warned that sales and operating profit growth will decline between 5% and 13% in 2026. The outlook reflects significant headwinds, primarily driven by lower pricing in its largest market, the United States,...
Novo Nordisk (NVO) shares have plummeted approximately 22% in the past week and 56% over the last year, trading near their 52-week low of roughly $39.63. This significant decline follows two major negative catalysts: a clinical trial failure for its CagriSema drug candidate and a...
A federal judge has allowed parts of a shareholder lawsuit against Novo Nordisk to proceed, alleging the company misled investors regarding its experimental weight-loss drug, CagriSema. The core dispute involves claims that Novo presented misleading information about the clinical trial design and tolerability of CagriSema...
Novo Nordisk (NVO) has initiated a clinical study to determine the minimum effective dosage for its oral Wegovy weight-loss medication, which utilizes semaglutide. The trial, involving 450 participants with a BMI of at least 27, began on August 12 and is scheduled to run through...
Novo Nordisk shares dropped approximately 6% on Tuesday following the release of its second-quarter financial results, which showed a miss in oral Wegovy sales despite an improved full-year outlook. The Danish pharmaceutical giant reported adjusted Q2 sales of 78.49 billion Danish kroner ($12.1 billion), representing...
Novo Nordisk (NVO) shares dropped sharply on July 31 after its experimental heart drug, Ziltivekimab, failed to meet the primary endpoint of the large-scale ZEUS late-stage trial. The Danish pharmaceutical giant had been counting on this cardiovascular asset to serve as a second growth engine...
On July 29, 2026, the Federal Trade Commission (FTC), joined by Utah and Los Angeles County, sued Hims & Hers Health, Inc. in Northern District of California. The lawsuit alleges deceptive practices regarding data sharing with advertising platforms like Meta and Snap, false claims about...
A U.S. federal judge in Trenton, New Jersey, ruled on Tuesday that Novo Nordisk must face a shareholder lawsuit alleging fraud regarding its CagriSema weight loss trial. The court found sufficient evidence that Martin Holst Lange, the company's former executive vice president of development and...
Novo Nordisk (NVO) faces a significant market reset in 2026, characterized by declining U.S. pricing, intense competition from Eli Lilly, and a pipeline setback with CagriSema missing its primary endpoint. Consequently, the company has guided to adjusted sales declines of 4% to 12% for the...
Novo Nordisk (NVO) is identified as a BUY opportunity because its business fundamentals are recovering faster than its current stock price, primarily driven by the historic U.S. launch of oral Wegovy. The article highlights that over 3 million prescriptions for oral Wegovy were filled in...
Novo Nordisk (NYSE:NVO) faces renewed investor scrutiny following a share-price decline of over 70% from its peak, driven by concerns that its core weight-loss franchise may lose ground to competitors. Despite these challenges, the company raised its 2026 sales and operating-profit growth guidance to a...
Novo Nordisk (NVO) has entered into an exclusive global licensing agreement with Nanexa to acquire PharmaShell coating technology. This platform is designed for long-acting peptide injectables targeting obesity, type 2 diabetes, and other cardiometabolic conditions, aiming to enable monthly or quarterly dosing schedules. Under the...
Novo Nordisk shares fell 10% over seven days, closing at EUR 33.94, as investors reacted negatively to a 2026-2030 revenue target that aligned with industry averages. Despite recent regulatory wins for FREHEMGO and Sogroya in Europe, the market remains fixated on the looming patent expiry...
Novo Nordisk is considering replacing its American Depositary Receipts (ADRs) with a direct listing on the New York Stock Exchange to enhance its profile among US investors, though the company states it is not actively pursuing this change. CEO Mike Doustdar highlighted that US operations...
A new study published in September 2026 reveals that patients on the lowest starter doses of GLP-1 weight-loss drugs still achieve measurable weight loss, though significantly less than at full recommended doses. Specifically, low-dose tirzepatide from Eli Lilly produced a 5.5% average weight loss over...
Haleon (HLN) is capitalizing on the side effects of GLP-1 weight-loss drugs, which are prescribed to millions of users including those taking Novo Nordisk's products. The company revealed a retail strategy on Sept. 16 involving dedicated 'GLP-1 destination shelves' at CVS Pharmacy to sell its...
Novo Nordisk (NVO) shares rose 2.83% to $42.89 after the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion on FREHEMGO, a next-generation bispecific antibody for haemophilia A. The regulatory body recommended marketing authorization for denecimig in adults and children...
Novo Nordisk (NVO) is executing a major strategic rebranding initiative, simplifying its corporate identity to 'Novo' with the motto 'Lasting Health Starts Now.' This transformation aims to enhance accessibility and public confidence while retaining its legal name, Novo Nordisk A/S. The company is simultaneously launching...
Morgan Stanley downgraded Novo Nordisk (NVO) from Equal-weight to Underweight, citing concerns over a looming patent cliff for its blockbuster drug semaglutide. The analyst team maintained a price target of 250 Danish crowns but warned that the current valuation does not adequately reflect a lackluster...
Novo Nordisk faces significant market pressure with its stock trading 30% below its January high, despite an aggressive share buyback program that has spent roughly 9 billion kroner. The company's equity has shed 13% year-to-date, currently trading at €38.41, well below the 50-day moving average...
